|
1
|
Nash K, Hafeez A and Hou S:
Hospital-acquired renal insufficiency. Am J Kidney Dis. 39:930–936.
2002.PubMed/NCBI View Article : Google Scholar
|
|
2
|
McCullough PA, Choi JP, Feghali GA,
Schussler JM, Stoler RM, Vallabahn RC and Mehta A: Contrast-induced
acute kidney injury. J Am Coll Cardiol. 68:1465–1473.
2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Pickering JW, Blunt IRH and Than MP: Acute
kidney injury and mortality prognosis in acute coronary syndrome
patients: A meta-analysis. Nephrology (Carlton). 23:237–246.
2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Narula A, Mehran R, Weisz G, Dangas GD, Yu
J, Genereux P, Nikolsky E, Brener SJ, Witzenbichler B, Guagliumi G,
et al: Contrast-induced acute kidney injury after primary
percutaneous coronary intervention: Results from the HORIZONS-AMI
substudy. Eur Heart J. 35:1533–1540. 2014.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Persson PB, Hansell P and Liss P:
Pathophysiology of contrast medium-induced nephropathy. Kidney Int.
68:14–22. 2005.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Heyman SN, Rosen S and Rosenberger C:
Renal parenchymal hypoxia, hypoxia adaptation, and the pathogenesis
of radiocontrast nephropathy. Clin J Am Soc Nephrol. 3:288–296.
2008.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Sadat U, Usman A, Boyle JR, Hayes PD and
Solomon RJ: Contrast medium-induced acute kidney injury.
Cardiorenal Med. 5:219–228. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kawai T and Akira S: The role of
pattern-recognition receptors in innate immunity: Update on
toll-like receptors. Nat Immunol. 11:373–384. 2010.PubMed/NCBI View
Article : Google Scholar
|
|
9
|
Cook DN, Pisetsky DS and Schwartz DA:
Toll-like receptors in the pathogenesis of human disease. Nat
Immunol. 5:975–979. 2004.PubMed/NCBI View
Article : Google Scholar
|
|
10
|
Lee JW, Kim SC, Ko YS, Lee HY, Cho E, Kim
MG, Jo SK, Cho WY and Kim HK: Renoprotective effect of paricalcitol
via a modulation of the TLR4-NF-κB pathway in
ischemia/reperfusion-induced acute kidney injury. Biochem Biophys
Res Commun. 444:121–127. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zhang D, Li Y, Liu Y, Xiang X and Dong Z:
Paclitaxel ameliorates lipopolysaccharide-induced kidney injury by
binding myeloid differentiation protein-2 to block toll-like
receptor 4-mediated nuclear factor-κB activation and cytokine
production. J Pharmacol Exp Ther. 345:69–75. 2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Stacul F, van der Molen AJ, Reimer P, Webb
JA, Thomsen HS, Morcos SK, Almén T, Aspelin P, Bellin MF and
Clement O: Contrast induced nephropathy: Updated ESUR contrast
media safety committee guidelines. Eur Radiol. 21:2527–2541.
2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Machado RA, Constantino de Souza L, Tomasi
CD, Rojas HA, Vuolo FS, Vitto MF, Cesconetto PA, de Souza CT,
Ritter C and Dal-Pizzol F: Sodium butyrate decreases the activation
of NF-κB reducing inflammation and oxidative damage in the kidney
of rats subjected to contrast-induced nephropathy. Nephrol Dial
Transplant. 27:3136–3140. 2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
O'Neill LA and Bowie AG: The family of
five: TIR-domain-containing adaptors in Toll-like receptor
signalling. Nat Rev Immunol. 7:353–364. 2007.PubMed/NCBI View
Article : Google Scholar
|
|
16
|
Takeda K, Kaisho T and Akira S: Toll-like
receptors. Annu Rev Immunol. 21:335–376. 2003.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Mudaliar H, Pollock C, Komala MG, Chadban
S, Wu H and Panchapakesan U: The role of Toll-like receptor
proteins (TLR) 2 and 4 in mediating inflammation in proximal
tubules. Am J Physiol Renal Physiol. 305:F143–F154. 2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Pulskens WP, Teske GJ, Butter LM, Roelofs
JJ, van der Poll T, Florquin S and Leemans JC: Toll-like receptor-4
coordinates the innate immune response of the kidney to renal
ischemia/reperfusion injury. PLoS One. 3(e3596)2008.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Morais C, Gobe G, Johnson DW and Healy H:
Anti-angiogenic actions of pyrrolidine dithiocarbamate, a nuclear
factor kappa B inhibitor. Angiogenesis. 12:365–379. 2009.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Cuzzocrea S, Chatterjee PK, Mazzon E, Dugo
L, Serraino I, Britti D, Mazzullo G, Caputi AP and Thiemermann C:
Pyrrolidine dithiocarbamate attenuates the development of acute and
chronic inflammation. Br J Pharmacol. 135:496–510. 2002.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Borghi SM, Fattori V, Ruiz-Miyazawa KW,
Bertozzi MM, Lourenco-Gonzalez Y, Tatakihara RI, Bussmann AJC,
Mazzuco TL, Casagrande R and Verri Jr WA: Pyrrolidine
dithiocarbamate inhibits mouse acute kidney injury induced by
diclofenac by targeting oxidative damage, cytokines and NF-κB
activity. Life Sci. 208:221–231. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Ii M, Matsunaga N, Hazeki K, Nakamura K,
Takashima K, Seya T, Hazeki O, Kitazaki T and Iizawa Y: A novel
cyclohexene derivative, ethyl
(6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate
(TAK-242), selectively inhibits toll-like receptor 4-mediated
cytokine production through suppression of intracellular signaling.
Mol Pharmacol. 69:1288–1295. 2006.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Takashima K, Matsunaga N, Yoshimatsu M,
Hazeki K, Kaisho T, Uekata M, Hazeki O, Akira S, Iizawa Y and Ii M:
Analysis of binding site for the novel small-molecule TLR4 signal
transduction inhibitor TAK-242 and its therapeutic effect on mouse
sepsis model. Br J Pharmacol. 157:1250–1262. 2009.PubMed/NCBI View Article : Google Scholar
|
|
24
|
González-Guerrero C, Cannata-Ortiz P,
Guerri C, Egido J, Ortiz A and Ramos AM: TLR4-mediated inflammation
is a key pathogenic event leading to kidney damage and fibrosis in
cyclosporine nephrotoxicity. Arch Toxicol. 91:1925–1939.
2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Rice TW, Wheeler AP, Bernard GR, Vincent
JL, Angus DC, Aikawa N, Demeyer I, Sainati S, Amlot N, Cao C, et
al: A randomized, double-blind, placebo-controlled trial of TAK-242
for the treatment of severe sepsis. Crit Care Med. 38:1685–1694.
2010.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Stewart JD, Hengstler JG and Bolt HM:
Contrast agent-induced nephrotoxicity: Role of oxidative stress and
apoptosis through the mitochondrial pathway. Arch Toxicol.
85:163–164. 2011.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Romano G, Briguori C, Quintavalle C, Zanca
C, Rivera NV, Colombo A and Condorelli G: Contrast agents and renal
cell apoptosis. Eur Heart J. 29:2569–2576. 2008.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Yano T, Itoh Y, Sendo T, Kubota T and
Oishi R: Cyclic AMP reverses radiocontrast media-induced apoptosis
in LLC-PK1 cells by activating A kinase/PI3 kinase. Kidney Int.
64:2052–2063. 2003.PubMed/NCBI View Article : Google Scholar
|
